Jun 21, 2010 12:00 EDT Viropharma DuoCort Pharma´s new physiological treatment for adrenal insufficiency improves patients’ quality of life. The company has also developed methods to optimize the dosage regimen which also contributes to an improvement in therapy over time. The Swedish pharmaceutical company presents this new data from its phase II/III trial at the 92nd annual ENDO congress in San Diego today.

Jun 17, 2010 00:30 EDT Viropharma The Swedish speciality pharma company DuoCort Pharma takes a step closer to the market by applying for market authorisation in EU for its new treatment for the rare and life threatening disease adrenal insufficiency, often referred to as Addison´s disease.